HR 7047
117th Congress
House
Lowering Costs by Improving Biosimilar Uptake Act
Official title: To amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes.
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2022
Referred to the Subcommittee on Health.
Mar 9, 2022
Referred to the House Committee on Energy and Commerce.
Mar 9, 2022
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Latest action
Referred to the Subcommittee on Health.
Plain-English summary
Lowering Costs by Improving Biosimilar Uptake Act
This bill allows for the omission of certain information relating to the strength of a product in a biosimilar application, as determined by the Food and Drug Administration.
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cite this page
U.S. Congress. (2026). H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-7047/
"H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-7047/.
H.R. 7047, 117th Cong. (2026), https://openamerica.io/bill/117-HR-7047/.
[H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act](https://openamerica.io/bill/117-HR-7047/)